$50.99 / month – $432.99
Buy Adipotide (FTPP) 5MG peptide – innovative fat loss research compound that targets adipose tissue vasculature. Promotes selective fat reduction through vascular targeting. 99% purity, USA-made, Same Day Shipping.
Adipotide (FTPP) is a research peptidomimetic that selectively targets prohibitin on adipose tissue vasculature to deliver a pro-apoptotic sequence, destroying fat-supplying blood vessels and inducing fat cell loss—distinct from traditional body or hormonal methods. Lab rodent and primate studies and a Phase 1 human trial showed dose-dependent, largely fat-selective weight loss and body gains, with possible preferential effects on visceral fat.
Clinical growth was halted in 2011 due to dose-limiting kidney toxicity, underscoring a narrow treatment window. This document details mechanism of action, research history, benefits, dosing and use protocols, safety and tracking, contraindications, control/ethical factors, and research-only product data.
What is Adipotide (FTPP)?
Adipotide peptide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), represents a revolutionary approach to fat loss research through selective vascular targeting. This innovative peptidomimetic compound consists of two functional components: a prohibitin-targeting sequence that directs the peptide to blood vessels supplying white adipose tissue, and a pro-apoptotic sequence that induces programmed cell death in those vessels.
The result is a highly selective mechanism for reducing fat mass that differs fundamentally from traditional body or hormonal approaches to weight care.
The growth of adipotide emerged from research into tumor vasculature targeting, where scientists discovered that certain peptide sequences could selectively bind to receptors on blood vessels supplying tumors. Researchers recognized that white adipose tissue, like tumors, needs extensive vascularization to keep its blood supply and nutrient supply. By adapting vascular targeting technology to adipose tissue, they created ftpp adipotide as a tool for studying targeted fat reduction through blood vessel destruction.
The cell-level structure of adipotide peptide is elegantly designed for its purpose. The targeting sequence (CKGGRAKDC) binds mainly to prohibitin, a protein that is preferentially expressed on the surface of endothelial cells lining blood vessels in white adipose tissue. This prohibitin expression pattern provides the selectivity that allows adipotide to distinguish fat tissue vasculature from blood vessels in other organs.
Once the peptide binds to prohibitin receptors, it is internalized into the endothelial cells through receptor-mediated endocytosis.
The second component of ftpp adipotide is the pro-apoptotic sequence D(KLAKLAK)2, a synthetic peptide that disrupts energy-cell membranes when it enters cells. In the bloodstream, this sequence is relatively inactive because it cannot cross cell membranes on its own. However, once the targeting sequence delivers it inside endothelial cells of adipose tissue blood vessels, the D(KLAKLAK)2 peptide disrupts energy-cell function, triggering apoptosis (programmed cell death) in those specific cells.
This leads to destruction of the blood vessels supplying fat tissue.
When blood vessels supplying adipose tissue are destroyed, the fat cells they nourish are deprived of oxygen and nutrients. Without enough blood supply, adipocytes (fat cells) undergo apoptosis and are gradually cleared by the body’s natural waste removal systems. This process results in reduction of fat mass in areas where adipotide has targeted the vasculature.
Importantly, the selectivity of the targeting mechanism means that blood vessels in other tissues are largely spared, providing a degree of specificity not achievable with systemic body interventions.
Research with adipotide has showed notable fat loss effects in lab models. Studies in obese rhesus monkeys showed that adipotide human trials possible was supported by dramatic weight loss of up to 27% over just 4 weeks of treatment, with fat mass reductions of about 39% while lean body mass was preserved.
These results were far more dramatic than often seen with dietary interventions or body compounds, highlighting the potency of vascular targeting as a fat loss mechanism.
Human clinical trials with adipotide peptide progressed to Phase 1 studies in obese patients with type 2 diabetes. These trials showed dose-dependent weight loss, with subjects losing major amounts of body weight over the treatment period. The fat loss was accompanied by gains in body parameters including blood glucose control and insulin response.
However, clinical growth was finally halted in 2011 due to kidney-related safety concerns that emerged at higher doses, though lower doses showed acceptable tolerability.
Despite the discontinuation of clinical growth, adipotide remains highly valuable for research purposes. The compound provides unique insights into adipose tissue biology, vascular targeting mechanisms, and the relationship between tissue blood supply and fat mass control. Researchers studying obesity, body makeup, and body health find ftpp adipotide to be an invaluable tool for grasp how targeted interventions might address fat buildup more selectively than traditional approaches.
When researchers buy adipotide from PrymaLab, they get pharmaceutical-grade peptide manufactured to the highest quality standards. Each 5mg vial contains 99% pure adipotide verified by third-party testing, ensuring reliable and reproducible research results. The peptide arrives as freeze-dried powder for maximum shelf life, ready for mixing with ++sterile water++ when research protocols begin.
Grasp Adipose Tissue Vasculature and Fat Biology
To fully appreciate how adipotide peptide works, it’s essential to understand the role of blood vessels in adipose tissue maintenance and growth. White adipose tissue, the main form of fat storage in the body, is a highly vascularized organ that needs extensive blood vessel networks to function. Each adipocyte must be within close proximity to a capillary to get oxygen and nutrients and to release stored fatty acids when energy is needed.
Adipose tissue vasculature is dynamic and responds to changes in fat mass. When people gain weight, adipose tissue expands through both hypertrophy (existing fat cells growing larger) and hyperplasia (formation of new fat cells from precursor cells). This expansion needs angiogenesis, the formation of new blood vessels, to ensure enough blood supply to the growing tissue.
Without enough vascularization, adipose tissue cannot expand effectively, and fat cells in poorly vascularized areas may undergo hypoxia and cell death.
The relationship between adipose tissue and its blood supply is bidirectional. Fat cells secrete factors that promote angiogenesis, including vascular endothelial growth factor (VEGF) and other pro-angiogenic signals. These factors boost endothelial cells to proliferate and form new blood vessels that penetrate the expanding fat tissue. Conversely, blood vessels provide not just oxygen and nutrients but also deliver hormones, immune cells, and other factors that regulate adipocyte function.
Importantly, the blood vessels supplying white adipose tissue express distinct cell-level markers that differentiate them from vasculature in other tissues. One of these markers is prohibitin, a protein that appears on the surface of endothelial cells in adipose tissue vasculature at higher levels than in most other organs. This differential expression pattern is what makes vascular targeting of fat tissue possible and is the basis for adipotide’s selectivity.
The concept of targeting adipose tissue vasculature for fat loss emerged from cancer research, where scientists developed peptides that could selectively bind to and destroy tumor blood vessels. Tumors, like adipose tissue, need extensive vascularization to grow and survive. By destroying tumor vasculature, researchers could starve tumors of their blood supply, causing tumor regression.
The same principle applies to ftpp adipotide and fat tissue — by destroying the blood vessels supplying adipose depots, the compound effectively starves fat cells of their blood supply.
When adipotide destroys blood vessels in adipose tissue, several processes occur. First, the immediate loss of blood flow causes hypoxia (oxygen deprivation) in nearby adipocytes. Fat cells are metabolically active and need oxygen for their many functions, so hypoxia triggers stress responses. Second, the loss of nutrient supply means adipocytes cannot keep their normal body activities or respond to hormonal signals effectively.
Third, without blood vessel access, adipocytes cannot release stored fatty acids into circulation when the body needs energy.
These combined stresses lead to adipocyte apoptosis, the programmed cell death pathway that allows cells to be removed without causing swelling or tissue damage. As fat cells die, they are engulfed by macrophages and other immune cells that clear the cellular debris. The fat stored in these cells is metabolized and removed from the body through normal body pathways.
Over time, this process results in reduction of fat mass in the targeted areas.
Interestingly, research suggests that adipotide peptide may preferentially affect visceral adipose tissue (fat surrounding internal organs) compared to under-skin fat (fat under the skin). Visceral fat is more highly vascularized than under-skin fat and may express higher levels of prohibitin on its blood vessels, making it more susceptible to adipotide’s targeting mechanism.
This preferential effect on visceral fat is very valuable from a health perspective, as visceral adiposity is more strongly linked with body disease, heart risk, and other health problems than under-skin fat.
The selectivity of ftpp adipotide for adipose tissue vasculature, while impressive, is not absolute. At higher doses, the compound can affect blood vessels in other tissues, very the kidneys, which led to the safety concerns that halted clinical growth. This highlights the importance of dose selection in research protocols and the need for careful tracking when using this powerful compound.
Grasp the balance between effect and safety is a key aspect of adipotide research.
Adipotide Mechanism of Action: Vascular Targeting for Fat Loss
The mechanism by which adipotide promotes fat loss involves a advanced sequence of cell-level events, all stemming from its dual-component design as a vascular targeting agent. Grasp these mechanisms in detail helps researchers design effective protocols and interpret research results accurately.
Main Mechanism — Prohibitin Targeting:
When adipotide peptide is gave, it enters the bloodstream and circulates throughout the body. The CKGGRAKDC targeting sequence at the N-terminus of the peptide has high binding affinity for prohibitin, a protein expressed on the surface of endothelial cells. While prohibitin is present in many tissues, its surface expression on blood vessel endothelium is very high in white adipose tissue, providing the selectivity that makes ftpp adipotide effective for targeted fat loss.
The binding of adipotide to prohibitin receptors on adipose tissue blood vessels is the key first step in its mechanism. This binding is specific and high-affinity, meaning the peptide preferentially builds up in adipose tissue vasculature compared to other organs. Once bound, the peptide-receptor complex is internalized through receptor-mediated endocytosis, a process where the cell membrane engulfs the bound peptide and brings it inside the cell in a vesicle.
Cellular Internalization and Pro-Apoptotic Action:
Once inside endothelial cells, the pro-apoptotic component of adipotide peptide becomes active. The D(KLAKLAK)2 sequence is a synthetic peptide designed to disrupt energy-cell membranes. In the bloodstream, this sequence cannot enter cells on its own because it lacks the power to cross cell membranes. However, once delivered inside cells by the targeting sequence, it gains access to intracellular compartments including mitochondria.
Mitochondria are the powerhouses of cells, creating the ATP energy that cells need to function. They have a double membrane structure, and the integrity of these membranes is essential for energy-cell function and cell survival. The D(KLAKLAK)2 peptide disrupts energy-cell membranes through its amphipathic structure, which allows it to insert into lipid bilayers and create pores or otherwise compromise membrane integrity.
When energy-cell membranes are disrupted, several catastrophic events occur in the cell. First, the electrochemical gradient across the inner energy-cell membrane collapses, halting ATP production. Second, pro-apoptotic factors normally sequestered in mitochondria are released into the cytoplasm, including cytochrome c, which starts the caspase cascade leading to apoptosis. Third, reactive oxygen species production increases, causing oxidant stress that further damages cellular components.
Endothelial Cell Apoptosis and Vessel Destruction:
The combined effects of energy-cell disruption trigger programmed cell death (apoptosis) in the endothelial cells that have internalized adipotide. Apoptosis is a controlled process where cells systematically dismantle themselves without causing swelling or damage to surrounding tissues. The dying endothelial cells detach from the blood vessel wall, leaving gaps in the vessel lining.
As multiple endothelial cells in a blood vessel undergo apoptosis, the structural integrity of the vessel is compromised. Blood vessels are mainly tubes made of endothelial cells supported by basement membrane and sometimes smooth muscle cells. When the endothelial lining is destroyed, the vessel can no longer keep blood flow effectively.
The vessel may collapse, become blocked by blood clots, or simply cease to function as a conduit for blood.
The destruction of blood vessels in adipose tissue has immediate results for the fat cells they supply. Without blood flow, adipocytes are deprived of oxygen (hypoxia) and nutrients (glucose, fatty acids, amino acids). They also lose the power to release stored fatty acids into circulation or respond to hormonal signals like insulin or catecholamines that normally regulate fat body function.
Adipocyte Apoptosis and Fat Mass Reduction:
The hypoxic and nutrient-deprived environment created by blood vessel destruction triggers stress responses in adipocytes. Fat cells try to adapt to these conditions, but if blood flow is not restored, they eventually undergo apoptosis themselves. The adipotide results saw in research studies reflect this second adipocyte death following vascular targeting.
As adipocytes die, they are recognized and cleared by macrophages, immune cells that specialize in removing dead cells and debris. The lipids stored in dying fat cells are released and metabolized through normal pathways. Some fatty acids are taken up by other tissues for energy, while others may be processed by the liver.
The overall effect is a reduction in fat mass in areas where ftpp adipotide has successfully targeted the vasculature.
Selectivity and Tissue Specificity:
The selectivity of adipotide peptide for adipose tissue vasculature is impressive but not absolute. The degree of selectivity depends on the differential expression of prohibitin on blood vessel endothelium in different tissues. White adipose tissue expresses high levels of surface prohibitin, making it a main target. However, other tissues also express prohibitin to varying degrees, and at higher doses of adipotide, off-target effects can occur.
The kidneys, in specific, showed susceptibility to adipotide effects in clinical trials, with kidney-related side effects being the main safety concern that halted growth. This likely reflects prohibitin expression in renal vasculature or glomerular cells. Grasp this dose-dependent selectivity is crucial for research protocol design, as lower doses may provide enough fat loss effects while minimizing off-target toxicity.
Temporal Dynamics and Dose-Response:
The time course of adipotide’s effects follows a predictable pattern. After use, the peptide circulates and binds to target vessels within hours. Endothelial cell apoptosis begins within 24-48 hours, and vessel destruction becomes apparent within several days. Adipocyte apoptosis and fat mass reduction occur over later weeks as the full effects of vascular targeting manifest.
The adipotide dosage used in research directly affects both the magnitude and selectivity of effects. Lower doses may preferentially target adipose tissue with minimal off-target effects, while higher doses produce more dramatic fat loss but increase the risk of affecting other tissues. Research protocols must carefully balance effect and safety through appropriate dose selection.
Regrowth and Reversibility:
An important aspect of adipotide’s mechanism is the possible for vascular regrowth after treatment cessation. Blood vessels have the capacity to regenerate through angiogenesis, and adipose tissue is very adept at boosting new vessel formation. After ftpp adipotide treatment ends, surviving adipocytes and adipose tissue stromal cells can secrete pro-angiogenic factors that promote new blood vessel growth.
This regrowth capacity means that the effects of adipotide may not be permanent without ongoing treatment or lifestyle changes to prevent fat regain. However, it also provides a safety margin — if off-target vascular effects occur, cessation of treatment allows for tissue healing through revascularization. This reversibility is an important consideration in research protocol design and safety planning.
Clinical Research and Adipotide Studies
Adipotide has been studied extensively in lab models and has progressed to human clinical trials, providing large data on its effects, safety profile, and possible uses. Grasp this research history helps researchers design effective protocols and interpret their findings in context.
Lab Studies — Proof of Concept:
Early research with adipotide peptide in rodent models showed the feasibility of vascular targeting for fat loss. Studies in diet-induced obese mice showed that use of the compound led to major reductions in body weight and fat mass. Histological review of adipose tissue from treated animals revealed evidence of blood vessel destruction and adipocyte apoptosis, confirming the proposed mechanism of action.
These first studies set up several important principles. First, they confirmed that ftpp adipotide could selectively target adipose tissue vasculature with relative sparing of other organs at appropriate doses. Second, they showed that the fat loss achieved was accompanied by gains in body parameters including insulin response and glucose tolerance.
Third, they showed that the effects were dose-dependent, with higher doses producing greater fat loss but also increased risk of adverse effects.
Primate Studies — Translational Research:
The most dramatic lab results came from studies in obese rhesus monkeys, which provided crucial translational data supporting human trials. In these studies, obese monkeys got daily under-skin injections of adipotide at doses ranging from 0.25 to 2.5 mg/kg body weight. The results were notable, with treated animals losing up to 27% of their body weight over 4 weeks of treatment.
Body makeup test revealed that the weight loss was mainly fat mass, with about 39% reduction in adipose tissue while lean body mass was largely preserved. This selective fat loss distinguished adipotide results from simple caloric restriction, which often causes loss of both fat and lean tissue. The monkeys also showed reductions in waist circumference, gains in insulin response, and decreases in markers of body dysfunction.
Importantly, the primate studies also revealed dose-limiting toxicities. At the highest doses tested (2.5 mg/kg), some animals developed kidney-related problems including increased serum creatinine and proteinuria, showing kidney damage. These findings suggested that while adipotide was highly effective for fat loss, there was a relatively narrow treatment window between effective doses and those causing adverse effects.
Phase 1 Human Clinical Trial:
Based on promising lab data, adipotide human trials progressed to Phase 1 studies in humans. These trials enrolled obese patients with type 2 diabetes and tested escalating doses of adipotide peptide gave as daily under-skin injections. The main goals were to assess safety, tolerability, and pharmacokinetics, with second endpoints including effects on body weight and body parameters.
The Phase 1 trial showed that adipotide could produce weight loss in humans, with dose-dependent effects on body weight. Subjects getting the compound lost greatly more weight than those getting placebo, with the magnitude of weight loss increasing with dose. The fat loss was accompanied by gains in glycemic control, with reductions in fasting glucose and HbA1c levels in diabetic subjects.
However, the trial also revealed safety concerns that would finally halt growth. At higher doses, some subjects experienced kidney-related adverse events including increased serum creatinine, proteinuria, and in some cases, more serious kidney dysfunction. These adipotide side effects were consistent with the kidney toxicity saw in primate studies and raised concerns about the compound’s safety profile at doses needed for major weight loss.
Clinical Growth Discontinuation:
In 2011, the pharmaceutical company developing adipotide (Arrowhead Research Corporation, in partnership with The University of Texas MD Anderson Cancer Center) announced the discontinuation of clinical growth. The decision was based on the kidney toxicity saw in clinical trials, which suggested that the treatment window between effective doses for weight loss and doses causing kidney damage was too narrow for safe treatment use.
The company stated that while the compound showed proof-of-concept for vascular targeting as a weight loss mechanism, the safety profile did not support continued growth for obesity treatment. The kidney effects appeared to be mechanism-based, resulting from adipotide’s effects on renal vasculature or glomerular cells, rather than off-target toxicity that might be engineered away through structural changes.
Research Implications and Ongoing Value:
Despite the discontinuation of clinical growth, adipotide remains highly valuable for research purposes. The extensive lab and clinical data provides important insights into vascular targeting as a fat loss mechanism, the role of adipose tissue blood supply in fat mass control, and the challenges of developing selective vascular targeting agents.
The research with ftpp adipotide has informed scientific grasp of adipose tissue biology and has inspired growth of next-generation compounds that might achieve similar fat loss effects with improved safety profiles. Grasp why adipotide caused kidney toxicity has helped researchers identify possible strategies for improving selectivity and reducing off-target effects in future vascular targeting agents.
For researchers who buy adipotide today, the peptide serves as a powerful tool for studying adipose tissue vasculature, vascular targeting mechanisms, and the relationship between tissue blood supply and fat mass. The well-characterized mechanism of action and extensive research history make it an ideal compound for controlled research studies exploring these important natural questions.
Lessons from Adipotide Research:
The adipotide research program provides several important lessons for peptide drug growth and obesity research. First, it shows that vascular targeting is a viable approach to fat loss, capable of producing dramatic reductions in fat mass. Second, it highlights the importance of selectivity in targeted therapies — even relatively selective compounds can cause off-target effects at higher doses.
Third, it shows that the treatment window for some mechanisms may be too narrow for safe treatment use, even if the mechanism is effective.
These lessons continue to inform research into obesity treatments and vascular targeting approaches. While adipotide peptide itself may not become a treatment agent, the principles it showed and the data it created remain valuable for advancing the field of obesity research and body medicine.
Adipotide Benefits for Fat Loss Research
The adipotide peptide benefits for fat loss research extend across multiple aspects of adipose tissue biology and body makeup, making it one of the most innovative tools available for studying targeted fat reduction. Grasp these benefits helps researchers design studies that maximize the compound’s research value.
Dramatic Fat Mass Reduction:
The most obvious benefit of adipotide is its power to promote large reductions in fat mass through a novel mechanism. Lab research showed fat mass reductions of up to 39% in obese primates over just 4 weeks of treatment, with body weight decreases of up to 27%. These dramatic effects far exceed what is often achievable through dietary interventions or traditional weight loss compounds, showing the potency of vascular targeting as a fat loss mechanism.
The magnitude of fat loss with ftpp adipotide makes it very valuable for research into maximum fat reduction possible and the limits of adipose tissue targeting. Researchers can study how much fat can be safely removed, how quickly fat loss can occur, and what factors limit the extent of fat reduction achievable through vascular targeting.
Selective Fat Loss with Lean Mass Preservation:
One of the most important adipotide peptide benefits is its selectivity for fat tissue, with relative preservation of lean body mass. Unlike caloric restriction or general body interventions that cause loss of both fat and muscle, adipotide results show predominantly fat loss. In primate studies, about 90% of weight loss was fat mass, with lean tissue largely kept.
This selective fat loss makes adipotide valuable for research into body makeup tuning and the mechanisms that find whether weight loss comes from fat or lean tissue. For adipotide bodybuilding research uses, the power to reduce fat while preserving muscle is very interesting, as it represents an ideal body makeup change for athletic performance and aesthetics.
Targeted Fat Depot Reduction:
Research suggests that adipotide peptide may preferentially affect certain fat depots over others, very visceral adipose tissue compared to under-skin fat. Visceral fat, which surrounds internal organs, is more highly vascularized and may express higher levels of prohibitin on its blood vessels, making it more susceptible to adipotide’s targeting mechanism.
This preferential effect on visceral fat is very valuable from a health research perspective. Visceral adiposity is strongly linked with body syndrome, type 2 diabetes, heart disease, and other health problems. The power to selectively reduce visceral fat while possibly sparing under-skin fat could provide insights into best fat distribution for body health.
Body Gains:
Beyond direct fat loss effects, adipotide research has shown gains in body parameters. Studies in obese primates and humans showed gains in insulin response, glucose tolerance, and glycemic control in diabetic subjects. These body benefits likely result from the reduction in fat mass, very visceral fat, which is metabolically active and adds to insulin resistance.
The body gains saw with ftpp adipotide make it valuable for research into the relationship between fat mass, fat distribution, and body health. Researchers can study whether the body benefits are simply due to fat loss or whether vascular targeting produces more effects on adipose tissue function and swelling signaling.
Novel Mechanism for Mechanistic Studies:
The unique vascular targeting mechanism of adipotide peptide provides opportunities for research that would not be possible with traditional fat loss approaches. Researchers can study the role of adipose tissue vasculature in fat mass control, the results of blood vessel destruction in fat tissue, the regrowth capacity of adipose tissue after vascular injury, and the selectivity determinants that allow targeting of fat tissue over other organs.
These mechanistic studies add to basic grasp of adipose tissue biology and may inform growth of next-generation targeted therapies. The power to selectively manipulate adipose tissue blood supply provides a powerful experimental tool for dissecting the complex biology of fat tissue.
Dose-Response Research:
The dose-dependent effects of adipotide allow for detailed dose-response studies that can set up relationships between dose, fat loss magnitude, selectivity, and adverse effects. Grasp the adipotide dosage that produces best fat loss with acceptable safety is crucial for research uses and informs grasp of the treatment window for vascular targeting approaches.
Researchers can design studies that test multiple dose levels, different dosing frequencies, and many treatment durations to fully characterize the compound’s effects. This dose-response data is valuable for optimizing research protocols and grasp the limits of vascular targeting as a fat loss mechanism.
Mix Research Possible:
Adipotide can be combined with other research compounds to study combined or additive effects on body makeup. Researchers might combine it with muscle-building peptides like ++Ipamorelin++ or ++CJC-1295++ to study whether simultaneous fat loss and muscle gain can be achieved. Mixes with body compounds could explore whether enhancing fat oxidation alongside vascular targeting produces superior results.
Such mix research could provide insights into best approaches for body makeup change and whether different mechanisms of fat loss work additively or synergistically. The power to study adipotide peptide alongside other compounds from our ++peptides for sale++ collection makes it a valuable component of full body research programs.
Translational Research Value:
The progression of adipotide from lab models through human clinical trials provides a complete translational research dataset. Researchers can compare effects across species, understand how findings in rodents and primates translate to humans, and identify factors that affect translatability of vascular targeting approaches.
This translational perspective is valuable for researchers developing next-generation compounds or studying the principles of targeted therapy growth. The adipotide human trials data, despite the program’s discontinuation, provides crucial data about human responses to vascular targeting that informs future research directions.
Research into Safety and Selectivity:
The safety challenges that halted adipotide clinical growth make it valuable for research into the determinants of selectivity and off-target effects in targeted therapies. Researchers can study why the compound affects kidney tissue, what factors find the treatment window, and how selectivity might be improved in future compounds.
Grasp the adipotide side effects and their mechanisms adds to broader knowledge about vascular targeting safety and the challenges of developing selective therapies. This safety research is as valuable as effect research for advancing the field and preventing similar problems in future compound growth.
Adipotide Dosage Protocols and Use
Finding appropriate adipotide dosage for research uses needs grasp the available lab and clinical data, considering research goals, and carefully balancing effect against safety concerns. The narrow treatment window saw in clinical trials makes dose selection very important for adipotide research.
Lab Dosage Data:
Animal studies with adipotide peptide tested a range of doses to set up effect and safety:
Rodent Studies:
Primate Studies:
Clinical Dosage Data:
Adipotide human trials in Phase 1 studies tested escalating doses:
Phase 1 Dose Escalation:
Research Dosage Rules:
Based on available data, research protocols with adipotide dosing should consider the following ranges:
Conservative Research Protocol:
Standard Research Protocol:
Advanced Research Protocol:
Adipotide Dosage Chart: Body Weight Conservative Dose (0.5 mg/kg) Standard Dose (1.0 mg/kg) Advanced Dose (1.5 mg/kg) 60 kg 30 mg (6 vials) 60 mg (12 vials) 90 mg (18 vials) 70 kg 35 mg (7 vials) 70 mg (14 vials) 105 mg (21 vials) 80 kg 40 mg (8 vials) 80 mg (16 vials) 120 mg (24 vials) 90 kg 45 mg (9 vials) 90 mg (18 vials) 135 mg (27 vials) 100 kg 50 mg (10 vials) 100 mg (20 vials) 150 mg (30 vials)
Note: Calculations based on 5mg vials. Use ++PrymaLab’s Peptide Calculator++for precise dosing.
Mixing Protocol:
Proper mixing of adipotide peptide is essential for accurate dosing and peptide shelf life:
Mixing Steps:
Use Technique:
Adipotide needs proper under-skin injection technique for best absorption and minimal discomfort:
Injection Sites:
Injection Procedure:
Dosing Frequency and Timing:
Unlike some peptides with longer half-lives, adipotide peptide needs daily use based on clinical trial protocols:
Daily Dosing Schedule:
Timing Factors:
Storage and Handling:
Proper storage keeps adipotide potency and shelf life:
Unreconstituted Peptide:
Mixed Solution:
Handling Precautions:
Research Protocol Design:
When designing research protocols with adipotide dosage, consider:
Dose-Response Studies:
Duration Studies:
Dose Escalation Protocols:
Safety Tracking:
Special Factors:
Body Weight Adjustments:
Personal Variability:
Mix Protocols:
Research Support Resources:
PrymaLab provides full support for researchers using adipotide:
When researchers buy adipotide peptide from PrymaLab, they get detailed mixing and use instructions with their order, ensuring proper handling and use of this valuable research compound.
SAFETY PROFILE AND SIDE EFFECTS
Grasp Adipotide Side Effects
The adipotide side effects profile is well-documented from lab and clinical research, providing important safety data for researchers. While the peptide showed promising effect for fat loss, kidney-related adverse events led to the discontinuation of clinical growth. Grasp these effects is crucial for responsible research use and appropriate safety tracking.
Lab Safety Data
Rodent Studies:
Early safety studies in mice and rats provided first toxicology data for adipotide peptide:
Common Effects in Rodents:
Dose-Limiting Toxicities:
Primate Safety Data:
Studies in obese rhesus monkeys provided crucial translational safety data:
Saw Adverse Events:
Important Findings:
Clinical Trial Safety Data
Phase 1 Human Trial:
The adipotide human trials in obese patients with type 2 diabetes revealed the safety profile in humans:
Common Adverse Events:
Kidney-Related Effects (Most Major):
Injection Site Reactions:
Gut Effects:
Heart Effects:
Other Effects:
Serious Adverse Events:
Mechanism of Kidney Toxicity
Grasp why adipotide causes kidney effects is important for research safety:
Prohibitin Expression in Kidneys:
The kidney toxicity likely results from adipotide peptide affecting renal vasculature or glomerular cells:
Glomerular Damage:
Reversibility:
Safety Tracking Recommendations
Researchers using ftpp adipotide should use full safety tracking:
Baseline Assessment:
Before starting research protocols:
Ongoing Tracking:
During research protocols:
Warning Signs Needing Immediate Attention:
Intervention Criteria:
Contraindications and Precautions
Certain conditions or circumstances warrant exclusion from adipotide research or need special precautions:
Absolute Contraindications:
Relative Contraindications (Need Careful Consideration):
Special Populations:
Elderly Subjects:
Diabetic Subjects:
Subjects with Multiple Risk Factors:
Managing Adverse Effects
If adipotide side effects occur during research, appropriate care strategies include:
For Kidney-Related Effects:
Mild Changes (Creatinine increase <0.3 mg/dL):
Moderate Changes (Creatinine increase 0.3-0.5 mg/dL):
Major Dysfunction (Creatinine increase >0.5 mg/dL):
For Injection Site Reactions:
For Gut Effects:
For Blood Pressure Changes:
General Care Principles:
Long-Term Safety Factors
While adipotide peptide clinical growth was relatively short-term, researchers should consider possible long-term effects:
Theoretical Long-Term Concerns:
Research Duration Recommendations:
Healing and Reversibility:
Comparison to Other Fat Loss Compounds
The adipotide side effects profile differs greatly from other fat loss research compounds:
Compared to Body Compounds:
Compared to Other Peptides:
Risk-Benefit Factors:
Control and Ethical Factors
Researchers using adipotide should be aware of control status and ethical obligations:
Control Status:
Research Ethics:
Banned Substance Status:
Risk Mitigation Strategies
To minimize risks when conducting research with ftpp adipotide:
Protocol Design:
Subject Selection:
Tracking and Follow-Up:
Quality Assurance:
Emergency Preparedness
Research protocols should include plans for managing possible emergencies:
Kidney Dysfunction:
Severe Adverse Reactions:
Allergic Reactions:
Safety Records
Proper records of safety aspects is essential:
Needed Records:
Reporting Requirements:
When researchers buy adipotide for sale from PrymaLab, full safety data is provided with each order, including known side effects, tracking recommendations, kidney function assessment rules, and emergency care protocols. This ensures researchers have the data needed for responsible and safe research use of this powerful but possibly toxic vascular targeting compound.
OFTEN ASKED QUESTIONS
What is Adipotide (FTPP)?
Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), is an innovative research peptide that promotes fat loss through a unique vascular targeting mechanism. Unlike traditional fat loss compounds that work through body or hormonal pathways, adipotide peptide selectively targets and destroys blood vessels supplying white adipose tissue. The compound consists of two functional components: a prohibitin-targeting sequence that directs it to adipose tissue vasculature, and a pro-apoptotic sequence that induces cell death in those blood vessels.
By cutting off the blood supply to fat tissue, ftpp adipotide causes fat cells to die and be cleared from the body, resulting in major fat mass reduction. Lab research in obese primates showed dramatic weight loss of up to 27% with fat mass reductions of about 39% over just 4 weeks.
While clinical growth was discontinued in 2011 due to kidney-related safety concerns, adipotide remains valuable for research into adipose tissue biology, vascular targeting mechanisms, and body makeup change.
How does Adipotide work for fat loss?
Adipotide peptide works through a advanced vascular targeting mechanism that is fundamentally different from traditional fat loss approaches. When gave, the peptide circulates in the bloodstream and selectively binds to prohibitin receptors that are preferentially expressed on endothelial cells lining blood vessels in white adipose tissue. Once bound, adipotide is internalized into these endothelial cells through receptor-mediated endocytosis.
Inside the cells, the pro-apoptotic D(KLAKLAK)2 component disrupts energy-cell membranes, triggering programmed cell death (apoptosis) in the endothelial cells. This leads to destruction of the blood vessels supplying fat tissue. Without enough blood supply, adipocytes (fat cells) are deprived of oxygen and nutrients, causing them to undergo apoptosis as well.
The dead fat cells are then cleared by the body’s natural waste removal systems, resulting in fat mass reduction. This vascular targeting approach allows ftpp adipotide to selectively reduce fat while preserving lean muscle mass, making it very interesting for body makeup research.
What are the benefits of Adipotide for research?
The adipotide peptide benefits for research are large and unique. Most notably, the compound produces dramatic fat loss through a novel vascular targeting mechanism, with lab studies showing fat mass reductions of up to 39% while preserving lean body mass. This selective fat loss makes adipotide valuable for studying body makeup tuning and the mechanisms finding whether weight loss comes from fat or muscle.
Research suggests the compound may preferentially target visceral adipose tissue (fat around organs) over under-skin fat, which is very valuable since visceral fat is more strongly linked with body disease. Adipotide results have also shown gains in body parameters including insulin response and glucose control. The unique mechanism provides opportunities for research into adipose tissue vasculature, the role of blood supply in fat mass control, and the growth of targeted therapies.
For adipotide bodybuilding research uses, the power to reduce fat while keeping muscle mass represents an ideal body makeup change. The compound’s progression through lab and clinical trials provides valuable translational research data for grasp how vascular targeting approaches translate across species.
What is the recommended Adipotide dosage?
Adipotide dosage recommendations are based on lab and clinical trial data, with careful consideration of the narrow treatment window between effective and toxic doses. Lab studies in obese primates showed best results at doses of 0.5-1.0 mg/kg body weight gave daily via under-skin injection, with higher doses (up to 2.5 mg/kg) producing greater fat loss but increased kidney toxicity risk.
Adipotide human trials in Phase 1 studies tested escalating doses starting at 0.05 mg/kg and increasing gradually, though specific maximum doses tested were not fully disclosed publicly.
For research protocols, conservative approaches might use 0.25-0.5 mg/kg daily, standard protocols 0.5-1.0 mg/kg daily, and advanced protocols up to 1.0-1.5 mg/kg daily with enhanced safety tracking. An adipotide dosage chart would show that for an 80 kg subject, a 0.5 mg/kg dose equals 40 mg daily (8 vials of 5mg), while 1.0 mg/kg equals 80 mg daily (16 vials).
Researchers should use ++PrymaLab’s Peptide Calculator++ for precise adipotide peptide dosage calculations. The adipotide dosing frequency is daily based on clinical protocols, with treatment durations often ranging from 2-8 weeks depending on research objectives and safety tracking capabilities.
How do I reconstitute and give Adipotide?
To reconstitute adipotide peptide, you’ll need ++sterile water++ and sterile syringes. Remove the plastic cap from the Adipotide 5MG vial and swab the rubber stopper with alcohol, allowing it to dry completely. Draw 2-2.5 mL of sterile water into a sterile syringe and inject it slowly down the side of the vial, not directly onto the powder, to avoid damaging the peptide structure.
Gently swirl the vial in a circular motion until the powder completely dissolves — never shake vigorously. The solution should be clear and colorless. For a 5mg vial with 2mL of water, you’ll have a level of 2.5mg/mL. For use, adipotide needs daily under-skin injection into areas like the abdomen (2 inches from navel), upper thighs, or upper arms.
Clean the injection site with alcohol and allow it to dry, pinch the skin to create a fold, insert the needle at a 45-90 degree angle depending on body fat thickness, and inject slowly over 5-10 seconds. Rotate injection sites daily to prevent tissue irritation. Store mixed solution refrigerated at 2-8°C and use within 14-21 days. Calculate your specific adipotide dose using ++PrymaLab’s Peptide Calculator++ based on your body weight and desired mg/kg dose.
What are Adipotide side effects?
The adipotide side effects profile is well-documented from lab and clinical research, with kidney-related effects being the most major concern. In adipotide human trials, the most common adverse events were kidney-related including increased serum creatinine (showing reduced kidney function), proteinuria (protein in urine), and decreased glomerular filtration rate. These effects were dose-dependent and led to the discontinuation of clinical growth in 2011.
Other reported adipotide side effects included injection site reactions (redness, swelling), gut effects (nausea, decreased appetite), mild blood pressure increases, and occasional fatigue or headaches. The kidney toxicity likely results from adipotide peptide affecting renal vasculature or glomerular cells, as prohibitin is expressed in kidney tissue. Importantly, most adverse effects were reversible upon discontinuation of treatment, though healing time varied among people.
Researchers using ftpp adipotide must use full safety tracking including baseline and regular kidney function tests, blood pressure tracking, and careful dose selection. The narrow treatment window between effective doses for fat loss and doses causing kidney toxicity needs careful protocol design and subject selection, with exclusion of anyone with pre-existing kidney disease or risk factors for kidney dysfunction.
Where can I buy Adipotide for research?
You can buy adipotide for research purposes from PrymaLab, a trusted supplier of pharmaceutical-grade research peptides. Our Adipotide (FTPP) 5MG vials contain 99% pure peptide verified by third-party testing, ensuring reliable and reproducible research results. Each vial arrives as freeze-dried powder for maximum shelf life during shipping and storage.
When you buy ftpp adipotide from PrymaLab, you get full records including certificates of test, mixing instructions, detailed dosing rules with adipotide peptide dosage chart, and extensive safety data including kidney tracking protocols.
We also provide research support resources including our ++Peptide Calculator++ for accurate dosing calculations and ++sterile water++ for proper mixing.
Fast, discreet shipping ensures your research materials arrive quickly and securely. Adipotide for sale at PrymaLab is intended for research purposes only and is not for human consumption outside approved research settings.
We provide technical support for protocol design and can answer questions about adipotide dosing and safety tracking to ensure responsible research use of this powerful vascular targeting compound.
What were the results of Adipotide human trials?
Adipotide human trials progressed to Phase 1 studies in obese patients with type 2 diabetes before clinical growth was discontinued. While complete results were not fully published, available data showed that adipotide produced dose-dependent weight loss in human subjects, with those getting the compound losing greatly more weight than placebo-treated controls.
The fat loss was accompanied by gains in body parameters including better glycemic control, with reductions in fasting glucose and HbA1c levels in diabetic subjects. These adipotide results showed that the dramatic fat loss effects saw in lab primate studies (up to 27% body weight loss and 39% fat mass reduction) could translate to humans.
However, the trials also revealed dose-limiting kidney toxicity, with subjects experiencing increased serum creatinine, proteinuria, and decreased kidney function at higher doses. These adipotide side effects were consistent with lab findings and finally led to the discontinuation of clinical growth in 2011. The narrow treatment window between effective doses for weight loss and doses causing kidney damage was deemed too narrow for safe treatment use.
Despite the program’s termination, the human trial data provides valuable proof-of-concept for vascular targeting as a fat loss mechanism and informs ongoing research into adipose tissue biology and targeted therapies.
Is Adipotide safe for research use?
Adipotide safety for research use needs careful consideration of the known risks, very kidney toxicity. While lab and clinical data show that the compound can be used in research settings, it has a narrow treatment window and needs full safety tracking. The kidney-related adipotide side effects that halted clinical growth — including increased creatinine, proteinuria, and decreased kidney function — were dose-dependent and often reversible upon discontinuation, but they represent major safety concerns.
For research purposes, adipotide peptide can be used safely with appropriate precautions including rigorous subject screening to exclude anyone with pre-existing kidney disease or risk factors, full baseline kidney function assessment, frequent tracking during treatment (weekly kidney function tests, urinalysis, blood pressure), clear protocols for dose reduction or discontinuation if adverse effects occur, and use of lower doses that provide better safety margins.
Research protocols should start with conservative doses (0.25-0.5 mg/kg) and escalate gradually only with careful tracking. The compound should not be used in pregnant or breastfeeding people, those with kidney disease, uncontrolled hypertension, or other contraindications. When used responsibly with proper precautions and tracking, ftpp adipotide provides valuable research insights while keeping acceptable safety margins, though researchers must remain vigilant for kidney-related adverse effects.
How does Adipotide compare to traditional fat loss methods?
Adipotide peptide differs fundamentally from traditional fat loss methods in both mechanism and effects. Traditional approaches including caloric restriction, increased physical activity, and body compounds work by creating an energy deficit or enhancing fat oxidation through systemic body changes. In contrast, ftpp adipotide uses vascular targeting to selectively destroy blood vessels supplying adipose tissue, cutting off the blood supply to fat cells and causing them to die.
This mechanism allows for more selective fat loss with better preservation of lean muscle mass — lab studies showed about 90% of weight loss was fat mass, compared to typical 60-75% with caloric restriction. Adipotide results also suggest preferential targeting of visceral adipose tissue over under-skin fat, which is advantageous since visceral fat is more metabolically harmful.
The magnitude of fat loss with adipotide far exceeds what’s often achievable with traditional methods, with primate studies showing 27% body weight loss and 39% fat mass reduction in just 4 weeks. However, this dramatic effect comes with major safety concerns, very kidney toxicity, that traditional methods don’t have. For adipotide bodybuilding research, the selective fat loss with muscle preservation represents an ideal body makeup change that’s hard to achieve through diet and exercise alone. The unique mechanism makes adipotide valuable for research into targeted fat reduction, though the safety profile prevented its growth as a treatment agent.
What is the difference between Adipotide 5MG and 10MG?
The difference between Adipotide 5MG and adipotide 10mg forms is simply the amount of peptide per vial, which affects dosing convenience and cost-effectiveness for research protocols. Both contain the same adipotide peptide with identical purity and quality standards. The 5MG vials are suitable for lower-dose protocols or shorter research studies, while 10MG vials may be more economical for higher-dose protocols or longer studies needing larger total amounts.
When calculating adipotide dosage, researchers should consider their total peptide needs based on body weight, desired mg/kg dose, treatment duration, and dosing frequency. For example, an 80 kg subject using 1.0 mg/kg daily would need 80 mg per day, which equals 16 vials of 5MG or 8 vials of 10MG.
The adipotide ftpp 10mg vials would provide more doses per vial, possibly reducing the number of reconstitutions needed and simplifying protocol use.
However, once mixed, peptide solutions should be used within 14-21 days, so researchers must balance vial size against usage timeline to minimize waste. Use ++PrymaLab’s Peptide Calculator++ to find which vial size best suits your research protocol. Both forms are available in our ++peptides for sale++ collection, and researchers can buy adipotide online in either level based on their specific needs.
Can Adipotide be combined with other research peptides?
Yes, adipotide peptide can possibly be combined with other research compounds to study combined or paired effects on body makeup, though such mixes need careful protocol design and enhanced safety tracking. Researchers might combine ftpp adipotide with muscle-building peptides like ++Ipamorelin++ or ++CJC-1295++ to study whether simultaneous fat loss and muscle gain can be achieved more effectively than with either compound alone.
The different mechanisms — vascular targeting for fat loss versus growth hormone boost for muscle growth — might work synergistically to optimize body makeup. Mixes with body compounds could explore whether enhancing fat oxidation alongside vascular targeting produces superior results. However, mix protocols need several important factors: possible interactions between compounds must be assessed, adipotide dosage may need adjustment when combined with other peptides, safety tracking must be enhanced to detect adverse effects from either compound or their interaction, and researchers should start with lower doses of each compound when combining.
The kidney toxicity risk with adipotide is very important to consider in mixes, as some other compounds might also affect kidney function. When designing mix research, include appropriate control groups getting each compound individually to distinguish combined from additive effects. PrymaLab’s full ++peptides for sale++ collection provides researchers access to multiple compounds for mix studies exploring best approaches to body makeup change.
What tracking is needed when using Adipotide?
Full tracking is essential when using adipotide due to the kidney toxicity risk that led to clinical growth discontinuation. Before starting research, baseline assessment must include complete medical history, physical review, and laboratory tests including serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), full urinalysis with protein measurement, complete blood count, full body panel, and liver function tests.
During research protocols with adipotide peptide, weekly tracking should include serum creatinine, urinalysis for protein, and eGFR calculation to detect early kidney function changes. Bi-weekly tracking should include full body panel, blood pressure measurement, body weight and makeup assessment, and physical review for adverse effects. Researchers must set up clear intervention criteria: mild kidney changes (creatinine increase <0.3 mg/dL) warrant close tracking and possible dose reduction, moderate changes (0.3-0.5 mg/dL increase) need holding treatment temporarily, and major dysfunction (>0.5 mg/dL increase) mandates immediate discontinuation.
Warning signs needing immediate attention include major creatinine increases, new or worsening proteinuria, decreased urine output, swelling in legs or face, persistent nausea, or severe injection site reactions. The adipotide dosing protocol should include plans for dose reduction or discontinuation based on tracking results. After treatment cessation, follow-up tracking should continue until kidney function returns to baseline, which may take weeks to months.
This intensive tracking is necessary to ensure early detection of adipotide side effects and prevent serious kidney damage. When researchers buy adipotide peptide from PrymaLab, detailed tracking protocols and safety rules are provided to support responsible research use.
Name: Michael Phelps
Title: Marketing Director & Biochemistry Specialist at Prymalab
Michael is an Air Force veteran and the Marketing Director at Prymalab. With a specialized background in biochemistry and over 10 years in the biotech industry, he applies military-grade precision to research standards and quality control. Michael is dedicated to bridging the gap between complex scientific studies and practical use, providing accurate, science-backed data on peptide protocols like Muscle Groth Peptides.
| Weight | N/A |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
Reviews
There are no reviews yet.